An interventional study of Levetiracetam and Valproic acid in Status Epilepticus, sponsored by RESnTEC, Institute of Research. Completed at 1 site in Pakistan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment
Since there is a significant degree of variability in the results of previous studies and there exists a thirst for local data regarding this topic, the current study was planned, with the objective of comparing the efficacy of levetiracetam versus valproic acid in pediatric patients with status epilepticus.
Early and sustained control of seizures is paramount in status epilepticus to save the life of the patient, and this warrants the use of the best drug based on evidence. Identifying a better drug in status epilepticus would add to the local data and help clinicians in making evidence-based decisions to opt for an appropriate treatment in case of failed response to benzodiazepines.
126 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.
This study's enrollment of 138 is above the median of 70 across 74 interventional studies indexed under Status Epilepticus.
Browse Status Epilepticus studies →RESnTEC, Institute of Research is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
In this group, patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.
Drug: Levetiracetam
Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.
Drug: Valproic acid
Patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.
Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.
Sustained control of seizure activity
Sustained control was labeled when there was no seizure activity on EEG and regain of consciousness for ≥ 24 hours
Time frame: 24 hours
Immediate cessation of seizure activity
Immediate cessation was defined as cessation of seizure activity within 15-30 minutes, after completion of drug infusion.
Time frame: 30 minutes
Plan to share: No — Data can be shared on a reasonable request.
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RESnTEC, Institute of Research